Welcome to our dedicated page for Senti Biosciences news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Biosciences stock.
Senti Biosciences, Inc. (Nasdaq: SNTI) is a pioneering biotechnology company focused on developing next-generation cell and gene therapies. The company leverages its proprietary Gene Circuit platform to engineer adaptive therapies for treating complex diseases, with a strong focus on oncology. Senti Bio's core technology harnesses synthetic biology to create precision gene circuits that can enhance the efficacy and safety of cellular therapeutics.
Founded by a team of engineers, scientists, and entrepreneurs, Senti Biosciences has rapidly advanced its research and development through strategic partnerships and significant investments. The company's innovative approach utilizes allogeneic chimeric antigen receptor natural killer (CAR-NK) cells integrated with gene circuits to address challenging diseases. Senti Bio’s primary product candidates include SENTI-202 for hematologic malignancies like Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), and SENTI-301A for the treatment of hepatocellular carcinoma (HCC).
- SENTI-202 employs Logic Gated CAR-NK cells designed to selectively target and eliminate cancer cells expressing CD33 and/or FLT3 antigens while sparing healthy bone marrow cells. The company received clearance from the U.S. FDA for its Investigational New Drug (IND) application and plans to initiate a Phase 1 clinical trial in 2024.
- SENTI-301A is designed for the treatment of HCC and is currently being developed in collaboration with Celest Therapeutics in China.
In addition to its primary pipeline, Senti Bio is actively exploring the potential of its Gene Circuit technology in other therapeutic areas and modalities, including partnerships with Spark Therapeutics and BlueRock Therapeutics. The company is committed to advancing its clinical programs and demonstrating the transformative potential of Gene Circuits in precision medicine.
Recent achievements include the establishment of a manufacturing partnership with GeneFab to support clinical-scale production and streamline operations to focus on key clinical programs. Senti Bio’s financial results reflect ongoing investments in research and development, with strategic efforts aimed at extending its cash runway and ensuring the successful advancement of its therapeutic candidates.
Senti Biosciences stays at the forefront of biotechnology innovation, dedicated to developing superior treatments for patients facing incurable diseases. Stay updated with Senti Bio’s latest developments and progress through their website and social media channels.
Senti Biosciences (Nasdaq: SNTI), a biotechnology company specializing in next-generation cell and gene therapies, has announced its participation in two upcoming investor conferences. The company will be present at:
1. H.C. Wainwright's 26th Annual Global Investment Conference in New York, NY, with a pre-recorded presentation available from September 9, 2024, at 7:00 a.m. ET.
2. Chardan's 8th Annual Genetic Medicines Conference in New York, NY, featuring a fireside chat on September 30, 2024, at 5:00 p.m. ET.
Senti Bio's flagship product, SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy, is currently in Phase 1 clinical trials. Investors can access webcasts and replays through the company's website for approximately 90 days following each event.
Senti Biosciences (Nasdaq: SNTI) reported Q2 2024 results and pipeline updates. Key highlights include:
- Ongoing patient dosing in Phase 1 trial of SENTI-202 for relapsed/refractory hematologic malignancies including AML
- Commencement of $8 million CIRM grant for SENTI-202 clinical development
- Plans to initiate pilot trial of SENTI-301A for HCC in China through Celest partnership in Q4 2024
- Q2 2024 financial results: $15.9 million cash, $9.2 million R&D expenses, $4.2 million G&A expenses, $11.2 million net loss
- Completed 1-for-10 reverse stock split to maintain Nasdaq listing compliance
Initial SENTI-202 efficacy data expected by year-end 2024, with durability data in 2025.
Senti Biosciences (Nasdaq: SNTI) has secured an $8 million grant from the California Institute for Regenerative Medicines (CIRM) to support the clinical development of SENTI-202. This investigational cell therapy is a potential first-in-class Logic Gated off-the-shelf CAR-NK treatment for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The Phase 1 clinical trial (NCT06325748) is currently enrolling adult patients with r/r CD33 and/or FLT3 expressing hematologic malignancies in the United States and Australia. Senti Bio expects to receive the first tranche of the grant in August 2024 and anticipates initial efficacy data by year-end 2024, with durability data following in 2025.
Senti Biosciences (Nasdaq: SNTI) has announced a 1-for-10 reverse stock split effective July 17, 2024, at 11:59 p.m. EDT. Trading on a split-adjusted basis will begin on July 18, 2024. This move will reduce outstanding shares from approximately 45.8 million to 4.6 million. The reverse split aims to address Nasdaq's minimum bid price requirement of $1.00 per share, which SNTI has not met since August 2023. Senti Bio has until August 5, 2024, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. The company believes this action will increase its stock price and resolve the compliance issue.
Senti Biosciences (Nasdaq: SNTI) has been awarded an $8 million grant by the California Institute for Regenerative Medicines (CIRM) for the clinical development of SENTI-202, a potential first-in-class Logic Gated CAR-NK cell therapy. This therapy targets relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The ongoing Phase 1 trial is enrolling adult patients in the US and Australia, evaluating two dosing levels. Initial efficacy data is expected by the end of 2024, with durability data following in 2025.
Senti Bio has dosed the first patient in the Phase 1 clinical trial of SENTI-202, a Logic Gated CAR-NK cell therapy for relapsed or refractory hematologic malignancies, including AML. The therapy targets CD33 and FLT3 expressing cells while sparing healthy bone marrow. Initial efficacy data is expected by 2024 end, with durability data in 2025. The trial is enrolling adult patients in the US and Australia, evaluating two dose levels. Senti Bio aims to redefine AML care with SENTI-202.
Senti Bio reported operational updates and financial results for the first quarter of 2024, highlighting the progress in their Phase 1 clinical trial of SENTI-202 for AML and SENTI-301A for HCC in collaboration with Celest. They also presented at ASGCT 2024 Annual Meeting on platform advancements. The company reported cash and cash equivalents of $23.7 million, with R&D expenses at $8.8 million and net loss of $12.1 million for the quarter. Senti Bio plans to participate in the BIO International Convention 2024 in San Diego, CA.
Senti Bio announced the publication of preclinical data on SENTI-202, a logic-gated CAR-NK cell therapy for AML, showing improved treatment outcomes and reduced toxicity. The data supports the upcoming Phase 1 clinical trial, with patient dosing expected in Q2 2024.
FAQ
What is the current stock price of Senti Biosciences (SNTI)?
What is the market cap of Senti Biosciences (SNTI)?
What is Senti Biosciences, Inc.?
What are Gene Circuits?
What are Senti Bio's main product candidates?
What is SENTI-202?
What is the status of SENTI-202?
Who are Senti Bio's partners?
What is the focus of SENTI-301A?
How is Senti Bio advancing its manufacturing capabilities?
Where can I find the latest news about Senti Biosciences?
What recent milestones has Senti Bio achieved?
